PR

• Kancera announces that an application for a clinical phase IIa study with KAND567 after heart attack has been submitted to the UK Medicines Agency (MHRA)

  24 May 2021

• Interim report for first quarter 2021, 1 January – 31 March 2021

  21 May 2021

• Kancera provides update on successful phase I study and planned phase II study with KAND567 treatment following heart attack

  15 January 2021

• Kancera appoints a Scientific Advisory Board with leading scientists in cardiology and immunology

  15 January 2021

• Agreement on development of HDAC6 inhibitors discontinued.

  2 December 2020